UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Infliximab as Rescue Treatment in Sweet’s Syndrome Related to Corticodependent Ulcerative Colitis

Journal of Crohn's and colitis, 2018-05, Vol.12 (6), p.755-756

2018

Volltextzugriff (PDF)

Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study

Journal of Crohn's and colitis, 2019-08, Vol.13 (8), p.996-1002

2019

Volltextzugriff (PDF)

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months

Digestive diseases and sciences, 2017-05, Vol.62 (5), p.1305-1312

2017

Volltextzugriff (PDF)

Does the Antitumor Necrosis Factor-α Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?

Journal of clinical densitometry, 2019-04, Vol.22 (2), p.195-202

2019

Volltextzugriff (PDF)

Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease

Digestive diseases and sciences, 2013-10, Vol.58 (10), p.2949-2954

2013

Volltextzugriff (PDF)

Erratum to: Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months

Digestive diseases and sciences, 2017-08, Vol.62 (8), p.2203-2203

2017

Volltextzugriff (PDF)

Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series

Revista española de enfermedades digestivas, 2011-06, Vol.103 (6), p.294-298

2011

Volltextzugriff (PDF)

P690 Monitoring ustekinumab levels in Inflammatory Bowel Disease in clinical practice: a window of opportunity

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1309-i1310

2024

Volltextzugriff (PDF)

P081 Therapeutic Drug Monitoring of infliximab in Crohn’s Disease: Cut-off points during maintenance therapy

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i181-i182

2022

Volltextzugriff (PDF)

P740 Results at 52 weeks of Intravenous Ustekinumab as Maintenance Treatment in Patients with Loss of Response to Subcutaneous Doses: A Multicenter Retrospective Observational Study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1385-i1387

2024

Volltextzugriff (PDF)

Rapidity of Onset of Response to Adalimumab (ADA) in Luminal Crohn Disease (CD). Data from Rapida Trial

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S776-S776

2017

Volltextzugriff (PDF)

P187 Clinical follow-up of patients with Crohn's disease treated with ustekinumab in our hospital

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S187-S188

2019

Volltextzugriff (PDF)

P335 Long-term follow-up of switching from original infliximab to infliximab biosimilar: real-world data

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S268-S269

2019

Volltextzugriff (PDF)

P493 Comparison of the efficacy of infliximab biosimilar (Remsima®) vs. infliximab original (Remicade®) in patients with inflammatory bowel disease

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S354-S355

2018

Volltextzugriff (PDF)

P519 Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months results

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S368-S369

2018

Volltextzugriff (PDF)

P391 Are cut-off ranges of Infliximab serum levels in Crohn’s disease always the same in clinical practice?

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S303-S304

2019

Volltextzugriff (PDF)

P618 Rapidity of onset of response to adalimumab in luminal Crohn's disease. Data from RAPIDA trial

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S395-S396

2017

Volltextzugriff (PDF)

P423 Early improvement in quality of life in patients with luminal Crohn's disease treated with adalimumab. Data from RAPIDA trial

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S291-S292

2017

Volltextzugriff (PDF)

P371 Prospective study of prevalence and incidence of vertebral fractures in long-term anti-TNF alpha maintenance therapy treatment for inflammatory bowel disease

Journal of Crohn's and colitis, 2014-02, Vol.8, p.S220-S220

2014

Volltextzugriff (PDF)

P176 PillCam colon (C2) vs colonoscopy in the assessment of colon mucosa in patients with ulcerative colitis

Journal of Crohn's and colitis, 2013-02, Vol.7, p.S79-S79

2013

Volltextzugriff (PDF)

Enfermedad inflamatoria intestinal y embarazo

Revista española de enfermedades digestivas, 2007-11, Vol.99 (11), p.671-671

2007

Volltextzugriff (PDF)

Enfermedad inflamatoria intestinal y embarazo

Revista española de enfermedades digestivas, 2007-11, Vol.99 (11)

2007

Volltextzugriff (PDF)

Enfermedad inflamatoria intestinal y embarazo Intestinal bowel disease and pregnancy

Revista española de enfermedades digestivas, 2007-11, Vol.99 (11), p.671-671

2007

Volltextzugriff (PDF)

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica

Revista española de enfermedades digestivas, 2011-06, Vol.103 (6), p.294-298

2011

Volltextzugriff (PDF)

P173 - Efficacy of adalimumab in patients with Crohn's disease and failure to therapy with infliximab

Journal of Crohn's and colitis, 2009-02, Vol.3 (1), p.S79-S79

2009

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(34)
Berichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(9)
Female
(7)
Gastroenterology & Hepatology
(7)
Life Sciences & Biomedicine
(7)
Science & Technology
(7)
Male
(6)
Adult
(5)
Oncology
(5)
Adalimumab
(4)
Crohn's Disease
(4)
Inflammatory Bowel Disease
(4)
Infliximab
(4)
Antibodies, Monoclonal - Therapeutic Use
(3)
Biochemistry
(3)
Care And Treatment
(3)
Gastroenterology
(3)
Gastroenterology And Hepatology
(3)
Hepatology
(3)
Medicine
(3)
Medicine & Public Health
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Infliximab as Rescue Treatment in Sweet’s Syndrome Related to Corticodependent Ulcerative Colitis

Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months

Does the Antitumor Necrosis Factor-α Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?

Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease

Erratum to: Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months

Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series

P690 Monitoring ustekinumab levels in Inflammatory Bowel Disease in clinical practice: a window of opportunity

P081 Therapeutic Drug Monitoring of infliximab in Crohn’s Disease: Cut-off points during maintenance therapy

P740 Results at 52 weeks of Intravenous Ustekinumab as Maintenance Treatment in Patients with Loss of Response to Subcutaneous Doses: A Multicenter Retrospective Observational Study

Rapidity of Onset of Response to Adalimumab (ADA) in Luminal Crohn Disease (CD). Data from Rapida Trial

P187 Clinical follow-up of patients with Crohn's disease treated with ustekinumab in our hospital

P335 Long-term follow-up of switching from original infliximab to infliximab biosimilar: real-world data

P493 Comparison of the efficacy of infliximab biosimilar (Remsima®) vs. infliximab original (Remicade®) in patients with inflammatory bowel disease

P519 Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months results

P391 Are cut-off ranges of Infliximab serum levels in Crohn’s disease always the same in clinical practice?

P618 Rapidity of onset of response to adalimumab in luminal Crohn's disease. Data from RAPIDA trial

P423 Early improvement in quality of life in patients with luminal Crohn's disease treated with adalimumab. Data from RAPIDA trial

P371 Prospective study of prevalence and incidence of vertebral fractures in long-term anti-TNF alpha maintenance therapy treatment for inflammatory bowel disease

P176 PillCam colon (C2) vs colonoscopy in the assessment of colon mucosa in patients with ulcerative colitis

Enfermedad inflamatoria intestinal y embarazo

Enfermedad inflamatoria intestinal y embarazo

Enfermedad inflamatoria intestinal y embarazo Intestinal bowel disease and pregnancy

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica

P173 - Efficacy of adalimumab in patients with Crohn's disease and failure to therapy with infliximab

Suchergebnisse filtern